Lilly and Resilience to Invest $750 Million in US Drug Manufacturing

Pharmaceutical companies Lilly and Resilience plan to invest a total of $750 million to expand drug manufacturing capacity in the United States. The investment will focus particularly on the production of biotechnological drugs and aims to strengthen the country's pharmaceutical supply chain. The majority of the investment will be used to establish new production facilities and modernize existing ones. The companies state that this step will increase drug manufacturing in the US, reduce foreign dependency, and improve access to critical medicines. Under the project, priority will be given to the production of biotechnological drugs used in areas such as cancer and autoimmune diseases. The investment is expected to contribute to regional economies and create new employment opportunities. With this investment, Lilly and Resilience aim to strengthen the US drug manufacturing infrastructure and build a more resilient system against potential future supply issues. The companies target completing the project within the next few years. This is not investment advice.